Bristol-Myers Cancer Drug Combination to Cost $256,000 a Year

Bristol-Myers Squibb Co. said its combination of two key cancer drugs, approved Thursday by U.S. regulators for a form of melanoma, will carry a list price of $256,000 a year on average.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.